- Home
- CYH vs FHTX Comparison
CYH vs FHTX Comparison
Compare CYH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- FHTX
- Stock Information
- Founded
- CYH 1985
- FHTX 2015
- Country
- CYH United States
- FHTX United States
- Employees
- CYH N/A
- FHTX N/A
- Industry
- CYH Hospital/Nursing Management
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- CYH Health Care
- FHTX Health Care
- Exchange
- CYH Nasdaq
- FHTX Nasdaq
- Market Cap
- CYH 623.8M
- FHTX 513.7M
- IPO Year
- CYH 1991
- FHTX 2020
- Fundamental
- Price
- CYH $3.15
- FHTX $5.14
- Analyst Decision
- CYH Hold
- FHTX Strong Buy
- Analyst Count
- CYH 6
- FHTX 5
- Target Price
- CYH $4.70
- FHTX $13.80
- AVG Volume (30 Days)
- CYH 4.0M
- FHTX 197.3K
- Earning Date
- CYH 10-23-2024
- FHTX 11-04-2024
- Dividend Yield
- CYH N/A
- FHTX N/A
- EPS Growth
- CYH N/A
- FHTX N/A
- EPS
- CYH N/A
- FHTX N/A
- Revenue
- CYH $12,551,000,000.00
- FHTX $25,515,000.00
- Revenue This Year
- CYH $1.15
- FHTX N/A
- Revenue Next Year
- CYH $1.14
- FHTX $11.54
- P/E Ratio
- CYH N/A
- FHTX N/A
- Revenue Growth
- CYH 0.81
- FHTX N/A
- 52 Week Low
- CYH $2.51
- FHTX $2.70
- 52 Week High
- CYH $6.29
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- CYH 32.04
- FHTX 27.35
- Support Level
- CYH $3.32
- FHTX $4.69
- Resistance Level
- CYH $3.53
- FHTX $5.70
- Average True Range (ATR)
- CYH 0.18
- FHTX 0.61
- MACD
- CYH 0.00
- FHTX -0.14
- Stochastic Oscillator
- CYH 15.28
- FHTX 16.24
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.